← Trevi Therapeutics, Inc. (TRVI) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Trevi Therapeutics, Inc. (TRVI)
Pharmaceutical Preparations · market cap $2.1B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
5
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Trevi Therapeutics (TRVI) is a small-cap pharmaceutical company with 34 employees and a ~$2.35B market cap built almost entirely around nalbuphine ER tablets, an extended-release formulation of the opioid agonist-antagonist nalbuphine in Phase 3 for Prurigo Nodularis and Uremic Pruritus, plus a Phase 2 program in Refractory Chronic Cough. The company carries only $19.4M in cash — roughly 3.5 months of runway — making near-term financing or a catalytic event existential.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Nalbuphine ER Tablets | Phase 3 | Prurigo Nodularis |
| nalbuphine HCl ER tablets 90 mg BID | Phase 3 | Prurigo Nodularis |
| NAL ER | Phase 2 | Refractory Chronic Cough |
| nalbuphine HCl ER tablets 60 mg BID | Phase 3 | Uremic Pruritus |
| nalbuphine HCl ER | Phase 3 | Uremic Pruritus |
Price & technical context
3-month
-20.7%
6-month
+19.2%
12-month
+51.4%
52-wk range
$9.55–$19.50
vs 50-day MA
-15.6%
vs 200-day MA
-0.3%
Realized vol
57.0%
Max drawdown
-29.5%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TRVI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.